Episode
Hospitals Are Using YETI Coolers for Heart Transplants — TransMedics Just Built Something Better (TMDX Q1 2026)
- Podcast
- Chip Stock Investor Podcast
- Published
- May 20, 2026
- Duration seconds
- 853
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/chip-stock-investor-podcast-6441813/episodes/hospitals-are-using-yeti-coolers-for-heart-transplants-transmedics-just-built-something-better-tmdx-q1-2026/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/chip-stock-investor-podcast-6441813/hospitals-are-using-yeti-coolers-for-heart-transplants-transmedics-just-built-something-better-tmdx-q1-2026.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
On the Q1 2026 earnings call for TransMedics, the CEO said something that stopped everyone in their tracks. Major transplant programs, he said, are going to Home Depot and buying YETI coolers to preserve human hearts before transplantation. None of those coolers are FDA-approved. None are validated for that purpose. That is the status quo TransMedics is trying to replace. This is CSI's update on TransMedics following their May 5th earnings report. TransMedics is not a semiconductor company — it sits in CSI's small bets basket, a collection of positions outside the core semiconductor thesis that Kasey follows closely. The company is building what it describes as the premier program for organ transplantation, combining a warm perfusion technology called the Organ Care System with its own aviation logistics network to dramatically improve the odds that a donated organ reaches its recipient in viable condition. The Q1 2026 numbers are solid. Revenue of $174 million, up 21% year over year, with 82% of organ transplants now covered by TransMedics' own logistics service. But the more interesting story is what comes next across four distinct growth catalysts. First, the CHOPS system — a new cold preservation device TransMedics just developed to serve the segment of the heart transplant market where cold storage is sufficient and warm perfusion is not required. Of 4,646 hearts transplanted in 2025, roughly 2,100 were preserved for less than four hours. That entire segment is currently going to Home Depot coolers. CHOPS is also the control arm TransMedics needed to run the ENHANCE Heart clinical trials — a clever solution to the problem of not being able to find a competitor willing to run head-to-head against their warm perfusion system. Second, European expansion — a logistics…